Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB (FINITE CHB)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: March 9, 2011
Last updated: November 12, 2013
Last verified: November 2013

Withdrawal of antiviral therapy can result in hepatic or alanine aminotransferase (ALT) flares as Hepatitis B Virus (HBV) replication resumes; however, in some patients, a flare exacerbates chronic hepatitis temporarily but can also result in viral clearance. Hepatic flares are common after stopping anti-HBV therapy.

Only patients who already are on treatment with tenofovir disoproxil fumarate (TDF) monotherapy or TDF in combination with lamivudine or emtricitabine for at least 4 years and who achieved and maintained virologic suppression (< 400 copies/mL) for 3.5 or more years will be included in this study. One treatment arm will stop the TDF therapy while the other treatment arm will continue the TDF therapy.

Patients who stop TDF (Arm A) will be monitored very closely with special focus on biochemical flares (especially ALT increases) and virological relapses (Hepatitis B viral load increases). If any subject in the stop therapy arm exceeds one or more predefined limits for such flares or relapses, TDF will be reinstituted.

The study will assess Hepatitis B surface antigen (HBsAg) loss (i.e. specific Hepatitis B virus components are no longer detectable) and seroconversion (occurrence of Hepatitis B surface antibody, a specific antibody which usually occurs after HBsAg loss) rates during study duration. The percentage of patients who need to restart TDF therapy in the stop arm will also be evaluated.

Condition Intervention Phase
Chronic Hepatitis B
Drug: Stopping TDF therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Proportion of participants with HBsAg loss at Week 144 in both study arms [ Time Frame: Week 144 ] [ Designated as safety issue: No ]
    The proportion of participants with HBsAg loss will be evaluated using the Kaplan-Meier (KM) product limit method. Participants who have not experienced HBsAg loss but discontinue from the study prior to Week 144 are considered censored at the last HBsAg collection date. Log-rank test statistic will be used to compare the time to HBsAg loss between the two treatment arms.

Secondary Outcome Measures:
  • Proportion of participants with seroconversion in both study arms [ Time Frame: Weeks 96 and 144 ] [ Designated as safety issue: No ]
    The proportion of participants with seroconversion at Weeks 96 and 144 and will be summarized.

  • Change from baseline in quantitative HBsAg (IU/mL) in both study arms [ Time Frame: Baseline to Week 144 ] [ Designated as safety issue: No ]
  • Proportion of participants who restart TDF therapy in Arm A [ Time Frame: Weeks 48, 96, and 144 ] [ Designated as safety issue: No ]
    The proportion of participants who restart TDF therapy in Arm A at Weeks 48, 96 and 144 will be estimated using the Kaplan-Meier (KM) product limit method. Participants who have not re-started TDF therapy but discontinue from the study will be considered as censored at the last laboratory collection date.

  • Proportion of participants with viral suppression in Arm A [ Time Frame: Baseline to Week 144 ] [ Designated as safety issue: No ]
    Viral suppression is defined as not having two consecutive HBV DNA ≥ 400 copies/mL.

  • Proportion of participants with ALT < upper limit of the normal range in Arm A [ Time Frame: Baseline to Week 144 ] [ Designated as safety issue: No ]
  • Proportion of participants with HBsAg loss at Week 96 in both study arms [ Time Frame: Week 96 ] [ Designated as safety issue: No ]

Estimated Enrollment: 90
Study Start Date: April 2011
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (stop TDF)
Subjects randomized to this arm will stop TDF therapy at baseline
Drug: Stopping TDF therapy
The TDF therapy will be stopped at baseline.
Other Names:
  • tenofovir
  • tenofovir disoproxil fumarate
  • Viread
No Intervention: Arm B (continue TDF)
Subjects randomized to this arm will continue their usual TDF therapy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic hepatitis B, hepatitis B e-antigen negative, hepatitis B e-antibody positive, and hepatitis B surface antigen-positive
  • Hepatitis B e Antigen (HBeAg)-negative at the beginning of TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine)
  • Received continuous TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine) treatment for at least 4 years prior to screening. If TDF has been used in combination with lamivudine or emtricitabine, lamivudine or emtricitabine must have been stopped at least 12 weeks prior to screening
  • Documented hepatitis B virus DNA (HBV DNA) < 400 copies/mL for at least 3.5 years prior to screening and at screening
  • ALT within normal range
  • α-fetoprotein (AFP) <= 50 ng/mL
  • Calculated creatinine clearance >= 70 mL/min by Cockcroft-Gault formula using ideal body weight
  • <= 10 kPa on Fibroscan assessment
  • A negative serum pregnancy test for female subjects
  • Adult subjects >= 18 years of age

Exclusion Criteria:

  • Known cirrhosis
  • Evidence of fibrosis >= Stage 3 (METAVIR) on liver biopsy or Fibroscan > 10 kPa within 6 months prior to screening
  • Documentation of confirmed episodes (i.e., 2 consecutive values) of HBV DNA > 400 copies/mL within 3.5 years prior to screening
  • History of decompensated liver disease (defined as direct [conjugated] bilirubin > 1.5 x upper limit of normal, prothrombin time (PT) > 1.5 x upper limit of normal, platelets < 75,000/mm³, serum albumin < 3.0 g/dL
  • History of clinical hepatic decompensation in the judgement of the investigator
  • Evidence of hepatocellular carcinoma
  • Significant bone disease (in the judgment of the investigator)
  • Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D infection
  • Known hypersensitivity to TDF, its metabolites, or formulation excipients
  • Concomitant therapy with disallowed medications
  • History of malignant disease
  • Lactating females
  • Females wishing to became pregnant during the duration of the stud
  • Subjects participating in another clinical trial can only be enrolled at the discretion of the Medical Monitor
  Contacts and Locations
Please refer to this study by its identifier: NCT01320943

Private Practice
Berlin, Germany, 10117
Charite CVK
Berlin, Germany, 13353
Leberzentrum am Checkpoint
Berlin, Germany, 10969
Zentrum für HIV und Hepatitis
Duesseldorf, Germany, 40237
J.W. Goethe Universitaetsklinikum
Frankfurt, Germany, 60590
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany, 20246
ifi Studien und Projekte GmbH
Hamburg, Germany, 20099
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Universitaetsklinik Heidelberg
Heidelberg, Germany, 69120
Gastroenterologische Gemeinschaftspraxis
Herne, Germany, 44623
Universitaetsklinikum Leipzig
Leipzig, Germany, 04103
Gemeinschaftspraxis Gastroenterologie
Leverkusen, Germany, 51375
Klinikum der LMU Grosshadern
Muenchen, Germany, 81377
Centrum interdisziplinaere Medizin
Muenster, Germany, 48143
Universitaetsklinik Tuebingen
Tuebingen, Germany, 72076
Universitaetsklinikum Ulm
Ulm, Germany, 89081
Sponsors and Collaborators
Gilead Sciences
Study Director: Eduardo Martins, MD Gilead Sciences
  More Information

No publications provided

Responsible Party: Gilead Sciences Identifier: NCT01320943     History of Changes
Other Study ID Numbers: GS-EU-174-0160, 2010-021925-12
Study First Received: March 9, 2011
Last Updated: November 12, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Gilead Sciences:
stopping oral antiviral therapy
HBsAg loss
restarting oral antiviral therapy

Additional relevant MeSH terms:
Hepatitis A
Hepatitis B
Hepatitis, Chronic
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Tin Fluorides
Tenofovir disoproxil
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents processed this record on April 15, 2014